IDEXX Laboratories, Inc. $IDXX Stock Position Lifted by Sumitomo Mitsui Trust Group Inc.

Key Points

• Sumitomo Mitsui Trust Group raised its stake in IDEXX by 4.3% to 209,106 shares (about $141.5M), and overall institutional ownership stands at 87.84% as several large funds (BNY Mellon, JPMorgan, Zurich, Principal, Invesco) boosted positions.
• Company insiders sold a total of 45,957 shares valued at $29.86M over the past 90 days — including EVP George Fennell and EVP Nimrata Hunt — leaving insiders with just 0.79% ownership.
• IDEXX beat quarterly expectations with $3.08 EPS vs. $2.93 estimate and $1.09B revenue, set FY2026 EPS guidance of 14.29–14.80, and carries a consensus "Moderate Buy" rating with an average target of $772.22.

Sumitomo Mitsui Trust Group Inc. lifted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 4.3% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 209,106 shares of the company's stock after purchasing an additional 8,626 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned 0.26% of IDEXX Laboratories worth $141,466,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently modified their holdings of IDXX. Bank of New York Mellon Corp grew its stake in shares of IDEXX Laboratories by 41.7% in the third quarter. Bank of New York Mellon Corp now owns 2,056,680 shares of the company's stock worth $1,313,992,000 after purchasing an additional 605,290 shares in the last quarter. JPMorgan Chase & Co. grew its stake in shares of IDEXX Laboratories by 60.0% in the third quarter. JPMorgan Chase & Co. now owns 869,930 shares of the company's stock worth $555,802,000 after purchasing an additional 326,348 shares in the last quarter. Zurich Insurance Group Ltd FI bought a new position in IDEXX Laboratories during the third quarter valued at about $143,730,000. Principal Financial Group Inc. boosted its stake in IDEXX Laboratories by 16.7% during the third quarter. Principal Financial Group Inc. now owns 1,315,722 shares of the company's stock valued at $840,638,000 after buying an additional 187,967 shares in the last quarter. Finally, Invesco Ltd. boosted its stake in IDEXX Laboratories by 14.0% during the third quarter. Invesco Ltd. now owns 1,320,263 shares of the company's stock valued at $843,503,000 after buying an additional 161,782 shares in the last quarter. Institutional investors own 87.84% of the company's stock.

Insider Buying and Selling at IDEXX Laboratories

In other news, EVP George Fennell sold 11,345 shares of the company's stock in a transaction on Tuesday, February 10th. The stock was sold at an average price of $646.72, for a total transaction of $7,337,038.40. Following the completion of the sale, the executive vice president directly owned 9,823 shares of the company's stock, valued at $6,352,730.56. This represents a 53.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Nimrata Hunt sold 1,758 shares of the company's stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $634.57, for a total value of $1,115,574.06. Following the sale, the executive vice president directly owned 18,141 shares of the company's stock, valued at approximately $11,511,734.37. This represents a 8.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 45,957 shares of company stock valued at $29,862,109 over the last 90 days. 0.79% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. Piper Sandler decreased their target price on IDEXX Laboratories from $775.00 to $750.00 and set a "neutral" rating for the company in a research note on Monday, February 9th. Wall Street Zen cut IDEXX Laboratories from a "strong-buy" rating to a "buy" rating in a research note on Saturday, February 28th. UBS Group decreased their target price on IDEXX Laboratories from $750.00 to $730.00 and set a "neutral" rating for the company in a research note on Tuesday, February 3rd. Weiss Ratings cut IDEXX Laboratories from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Thursday, January 29th. Finally, BTIG Research decreased their target price on IDEXX Laboratories from $830.00 to $800.00 and set a "buy" rating for the company in a research note on Tuesday, February 3rd. Seven research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $772.22.

IDEXX Laboratories Stock Performance

Shares of IDXX stock opened at $563.00 on Monday. The stock has a 50-day simple moving average of $607.41 and a 200 day simple moving average of $656.92. IDEXX Laboratories, Inc. has a fifty-two week low of $375.05 and a fifty-two week high of $769.98. The stock has a market capitalization of $44.72 billion, a P/E ratio of 43.08, a P/E/G ratio of 3.42 and a beta of 1.72. The company has a quick ratio of 0.90, a current ratio of 1.23 and a debt-to-equity ratio of 0.23.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its earnings results on Monday, February 2nd. The company reported $3.08 EPS for the quarter, beating the consensus estimate of $2.93 by $0.15. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The business had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same period in the prior year, the business posted $2.53 earnings per share. IDEXX Laboratories's revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, sell-side analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.